High expression of miR-155 and miR-21 in the recurrence or metastasis of non-small cell lung cancer

Xu,Shuang; Shi,Lei

doi:10.3892/ol.2019.10337

High expression of miR-155 and miR-21 in the recurrence or metastasis of non-small cell lung cancer

Authors:
- Shuang Xu
- Lei Shi
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, Daqing Oil Field General Hospital, Daqing, Heilongjiang 163000, P.R. China, Department of Hematology and Oncology, Daqing Longnan Hospital, Daqing, Heilongjiang 163000, P.R. China
Published online on: May 8, 2019 https://doi.org/10.3892/ol.2019.10337
Pages: 758-763
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

High expression of miR-155 and miR-21 in the recurrence or metastasis of non-small cell lung cancer (NSCLC) was investigated. Retrospective analysis on the clinical information of 180 patients with NSCLC was carried out. The patients were admitted to Daqing Oil Field General Hospital from February 2012 to March 2015 and they were the research group. Moreover, the physical examination information of 88 normal medical examinees were selected at the same period of time as the control group. In the research group, 68 patients diagnosed with NSCLC were the newly diagnosed group and 112 cases of recurrence or metastasis of NSCLC were the recurrence group. The quantitative real-time polymerase chain reaction was used to detect the expression levels of serum miR-115 and miR-21. In addition, the expression levels between miR-155 and miR-21 and the relationship between the recurrence rate and metastasis of NSCLC were analyzed. The impact on the prognosis of patients were also analyzed. The expression levels of serum miR-155 and miR-21 were higher in the research group than those in the control group (P<0.05). The expression levels of serum miR-155 and miR-21 were higher in the recurrence group than those in the newly diagnosed group (P<0.05). We followed up the patients in the research group for 36 months, the median survival time and mortality rate in the recurrence group was higher than that of in the newly diagnosed group (χ2=9.705, P<0.01). In conclusion, miR-155 and miR-21 were highly expressed in the serum of patients, however, the recurrence and metastasis of NSCLC were even higher. The highly expressed levels of miR-155 and miR-21 were associated with the recurrence and metastasis in NSCLC patients, affecting the prognosis of patients.

View Figures

View References

1	Scagliotti GV, Szczesna A, Ramlau R, Cardenal F, Mattson K, Van Zandwijk N, Price A, Lebeau B, Debus J and Manegold C: Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer. Br J Cancer. 94:1375–1382. 2006. View Article : Google Scholar : PubMed/NCBI
2	Kocić B, Petrović B, Rancić N and Ilić M: Lung cancer trends in Southeastern Serbia. Cent Eur J Public Health. 21:17–21. 2013. View Article : Google Scholar : PubMed/NCBI
3	Meza R, Meernik C, Jeon J and Cote ML: Lung cancer incidence trends by gender, race and histology in the United States, 1973–2010. PLoS One. 10:e01213232015. View Article : Google Scholar : PubMed/NCBI
4	Pathak AK, Bhutani M, Mohan A, Guleria R, Bal S and Kochupillai V: Non small cell lung cancer (NSCLC): Current status and future prospects. Indian J Chest Dis Allied Sci. 46:191–203. 2004.PubMed/NCBI
5	Haroun RA, Zakhary NI, Mohamed MR, Abdelrahman AM, Kandil EI and Shalaby KA: Assessment of the prognostic value of methylation status and expression levels of FHIT, GSTP1 and p16 in non-small cell lung cancer in Egyptian patients. Asian Pac J Cancer Prev. 15:4281–4287. 2014. View Article : Google Scholar : PubMed/NCBI
6	Kuo CH, Wu CY, Lee KY, Lin SM, Chung FT, Lo YL, Liu CY, Hsiung TC, Yang CT and Wu YC: Chronic obstructive pulmonary disease in stage I non-small cell lung cancer that underwent anatomic resection: The role of a recurrence promoter. COPD. 11:407–413. 2014. View Article : Google Scholar : PubMed/NCBI
7	Kumpiro S, Sriuranpong V and Areepium N: Impact of the copper transporter protein 1 (CTR1) polymorphism on adverse events among advanced nonsmall cell lung cancer patients treated with a carboplatin/gemcitabine regimen. Asian Pac J Cancer Prev. 17:4391–4394. 2016.PubMed/NCBI
8	Merino MJ, Gil S, Macias CG and Lara K: The unknown microRNA expression of male breast cancer. Similarities and differences with female ductal carcinoma. Their role as tumor biomarker. J Cancer. 9:450–459. 2018. View Article : Google Scholar : PubMed/NCBI
9	Feng B, Zhang K, Wang R and Chen L: Non-small-cell lung cancer and miRNAs: Novel biomarkers and promising tools for treatment. Clin Sci (Lond). 128:619–634. 2015. View Article : Google Scholar : PubMed/NCBI
10	Ribas J, Ni X, Castanares M, Liu MM, Esopi D, Yegnasubramanian S, Rodriguez R, Mendell JT and Lupold SE: A novel source for miR-21 expression through the alternative polyadenylation of VMP1 gene transcripts. Nucleic Acids Res. 40:6821–6833. 2012. View Article : Google Scholar : PubMed/NCBI
11	Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K and Yang GH: MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta. 411:846–852. 2010. View Article : Google Scholar : PubMed/NCBI
12	Xie Q, Chen X, Lu F, Zhang T, Hao M, Wang Y, Zhao J, McCrae MA and Zhuang H: Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma. Cancer. 118:2431–2442. 2012. View Article : Google Scholar : PubMed/NCBI
13	Gao Y, Fu S, Jiang W, Li B, Tian Y and Fu X: Association of MiR-155 expression with prognosis in resected stage III non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 17:417–423. 2014.(In Chinese). PubMed/NCBI
15	Liu F, Song D, Wu Y, Liu X, Zhu J and Tang Y: MiR-155 inhibits proliferation and invasion by directly targeting PDCD4 in non-small cell lung cancer. Thorac Cancer. 8:613–619. 2017. View Article : Google Scholar : PubMed/NCBI
16	Gyoba J, Shan S, Roa W and Bédard EL: Diagnosing lung cancers through examination of micro-RNA biomarkers in blood, plasma, serum and sputum: A review and summary of current literature. Int J Mol Sci. 17:4942016. View Article : Google Scholar : PubMed/NCBI
17	Roesel C, Terjung S, Weinreich G, Hager T, Chalvatzoulis E, Metzenmacher M and Welter S: Sarcomatoid carcinoma of the lung: A rare histological subtype of non-small cell lung cancer with a poor prognosis even at earlier tumour stages. Interact Cardiovasc Thorac Surg. 24:407–413. 2017.PubMed/NCBI
18	Liu J, Shi K, Chen M, Xu L, Hong J, Hu B, Yang X and Sun R: Elevated miR-155 expression induces immunosuppression via CD39(+) regulatory T-cells in sepsis patient. Int J Infect Dis. 40:135–141. 2015. View Article : Google Scholar : PubMed/NCBI
19	Liu Y, Luo F, Wang B, Li H, Xu Y, Liu X, Shi L, Lu X, Xu W, Lu L, et al: STAT3-regulated exosomal miR-21 promotes angiogenesis and is involved in neoplastic processes of transformed human bronchial epithelial cells. Cancer Lett. 370:125–135. 2016. View Article : Google Scholar : PubMed/NCBI
20	Wang Y, Li J, Tong L, Zhang J, Zhai A, Xu K, Wei L and Chu M: The prognostic value of miR-21 and miR-155 in non-small-cell lung cancer: A meta-analysis. Jpn J Clin Oncol. 43:813–820. 2013. View Article : Google Scholar : PubMed/NCBI
21	Xue X, Liu Y, Wang Y, Meng M, Wang K, Zang X, Zhao S, Sun X, Cui L, Pan L, et al: MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN. Oncotarget. 7:84508–84519. 2016. View Article : Google Scholar : PubMed/NCBI
22	Yang M, Shen H, Qiu C, Ni Y, Wang L, Dong W, Liao Y and Du J: High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur J Cancer. 49:604–615. 2013. View Article : Google Scholar : PubMed/NCBI
23	Lasithiotaki I, Tsitoura E, Koutsopoulos A, Lagoudaki E, Koutoulaki C, Pitsidianakis G, Spandidos DA, Siafakas NM, Sourvinos G and Antoniou KM: Aberrant expression of miR-21, miR-376c and miR-145 and their target host genes in Merkel cell polyomavirus-positive non-small cell lung cancer. Oncotarget. 8:112371–112383. 2016.PubMed/NCBI
24	Donnem T, Eklo K, Berg T, Sorbye SW, Lonvik K, Al-Saad S, Al-Shibli K, Andersen S, Stenvold H, Bremnes RM, et al: Prognostic impact of MiR-155 in non-small cell lung cancer evaluated by in situ hybridization. J Transl Med. 9:62011. View Article : Google Scholar : PubMed/NCBI
25	Gironella M, Seux M, Xie MJ, Cano C, Tomasini R, Gommeaux J, Garcia S, Nowak J, Yeung ML, Jeang KT, et al: Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA. 104:16170–16175. 2007. View Article : Google Scholar : PubMed/NCBI
26	Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI